The threat of bacterial biofilms

Bacteria naturally prefer biofilm environments

  • Slime-like, protected communities of bacteria that shield bacteria from immune or antibiotic attack
  • Composed of extracellular polymeric substance (EPS) and a scaffolding matrix of extracellular DNA (eDNA) and “linchpin” (red) binding proteins

Biofilms protect bacteria
and drive resistance

Drive antibiotic failure, antibiotic resistance, inflammatory responses, and poor clinical outcomes

  • Responsible for approximately 80 percent of human bacterial infections
  • Biofilm-encased bacteria can be up to 1,000 times more resistant to antibiotics than those unprotected by biofilms

The Clarametyx Technology

Powerful Non-Antibiotic and pathogen-agnostic biologic technology

CMTX-101 (purple) antibodies capture and remove key linchpin proteins (red), resulting in rapid biofilm collapse

Key modes of action:

  • Immune-enabling: Enables a more efficient immune reaction to eliminate disease-causing bacteria
  • Antibiotic-sensitizing: Enhances the effectiveness of antibiotic activity
  • Inflammation-suppressing: Decreases biofilm-associated inflammation and reduces inflammatory reaction without impairing immune response

Biofilm collapse
drastically increases
bacterial vulnerability

  • Antibiotic susceptibility increased by 4 to 8 fold
  • Antibiotics and innate immune effectors able to access bacteria

Unprotected bacteria
are rapidly destroyed

  • First line antibiotics and innate immune response more effective
  • Multi-faceted pro-stewardship benefits reduced potential for development of antibiotic resistance
  • High potential for cost-effective clinical benefit